India, Dec. 27 -- By Shalini Bhardwaj

New Delhi [India], December 27 (ANI): Indian Immunologicals Limited (IIL), one of India's leading vaccine manufacturers, has issued a clarification regarding recent reports surrounding its human anti-rabies vaccine, Abhayrab(R).

The company strongly refuted the over-cautious and misplaced reference to 2023 made in a recent Australian health advisory, stressing that the advisory does not reflect the current situation. Abhayrab(R) has been manufactured by IIL since 2000, with more than 210 million doses supplied across India and 40 countries, and continues to hold a 40% market share in India.

The Australian Technical Advisory Group on Immunisation has stated that counterfeit (fake) batches of the rab...